EGFR and large cell neuroendocrine carcinoma: Although EGFR/RB1/TP53 triple mutation seems to identify a group of patients at the highest risk for SCLC transformation, biomarkers to predict transformation to SCC, EMT, and LCNEC are currently lacking.